Despite advancing technologies, clinical trials still struggle to meet patient enrolment goals. Slow enrolment directly impacts schedule and budget, with each day of delay carrying cripplingly high costs.
Successful, timely patient recruitment is directly linked to effective site selection. Conversely, selecting the wrong site can negatively impact recruitment or result in total failure to enrol patients.
Join us to learn how advancements in AI can help pharma and biotech identify the best sites for their clinical trials through the harnessing of Big Data. Topics and learnings include:
- Insights on transitioning from a state of data overload to one of data driven, informed decision-making
- The role of Artificial Intelligence in optimising site identification and selection
- Expected and unexpected downstream benefits of an AI-enabled site selection strategy
Speaker
.png?crop=yes&w=240&h=240&itok=7L6kvIKC){kind=icon}
Travis Caudill
Travis Caudill has over 17years’ experience in clinical trial strategy, global feasibility and site identification, and is an expert in clinical trial modelling and simulation. As Vice President, Feasibility and Clinical Informatics at ICON, he oversees a team of world-class feasibility experts and data scientists who process, interrogate, and analyse data to support effective data driven decisions for pharma, biotech, and medical device sponsors.
Audience
This webinar will be useful for biopharma professionals working in:
- Site identification
- Site selection
- Clinical operations
- Procurement / outsourcing
- Quality / compliance